Ostarine (MK-2866 / Enobosarm)
MK-2866 · Enobosarm
Non-steroidal SARM; mild, used in cutting/recomp. Simple model (estimated).
Key takeaways
- Mild, well-studied SARM: phase 2 trials showed dose-dependent lean mass gains at just 1–3 mg daily.
- Estimated 24-hour half-life supports once-daily dosing; the plotter curve is modeled from LGD-4033 data.
- Suppression, lipid shifts, and liver enzymes worsen at off-label doses, so bloodwork and PCT planning matter.
- Unapproved and WADA-prohibited; grey-market products are frequently mislabeled or contaminated.
Reported dosing protocols
Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.
| Use case | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Clinical trial (phase 2) | 1–3 mg | Oral | Once daily | Up to 12 weeks |
| Physique (community) | 10–25 mg | Oral | Once daily | 6–8 weeks |
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 24 hours
- Bioavailability
- 100%
- Typical dose
- 10–25 mg
Harm reduction
- Aromatizes
- No
- Hepatotoxicity
- mild
- Injection frequency
- Oral, daily
Frequently asked questions
Is ostarine legal and approved?
No approved medical use exists anywhere. It's sold as a research chemical, prohibited by WADA, and banned from dietary supplements in several countries. Grey-market products are frequently mislabeled or contain different compounds than the label claims.
How suppressive is ostarine?
Dose-dependent. Trial doses (1–3 mg) caused mild, reversible changes; community doses (10–25 mg) commonly show measurable LH, FSH, and total testosterone drops on bloodwork. A PCT plan before starting is standard harm-reduction practice, not an afterthought.
Is the plotter's ostarine curve accurate?
It's an estimate. Published human PK data are limited, so the profile is modeled by comparison to LGD-4033. Use it for relative timing (peak shape, accumulation, washout) rather than exact nanogram-per-mL values.
References
- Ostarine PK (estimated) — Estimated by comparison to LGD-4033.
- Dalton et al., J Cachexia Sarcopenia Muscle 2011 — phase 2 RCT — GTx-024 improved lean body mass and physical function at 1–3 mg daily over 12 weeks.
- GTx-024 ADME study, Xenobiotica 2013 — Absorption, distribution, metabolism, and excretion data behind the PK estimate.
Related articles
Related compounds
Comments
Loading comments…